Illumina markets whole-genome sequencing solution for highly sensitive MRD research

J. Craig Venter’s work was foundational to cancer advancement of the past 25 years

J. Craig Venter, a scientist and entrepreneur who raced against the Human Genome Project to decode the human genome, died on April 29, 2026. He was 79.

May 08, 2026

Vol.52 No.18

By Joyce Ohm

In Brief

City of Hope to evaluate Quest Diagnostics’ Haystack MRD for guiding patient management in multiple cancers

Quest Diagnostics, a provider of diagnostic information services, announced that City of Hope is implementing Haystack MRD, a circulating-tumor DNA minimal residual disease test, for clinical trial participants with solid tumor cancers to help guide disease management for patients being treated for breast, colorectal, ovarian, and prostate cancer.

April 24, 2026

Vol.52 No.16

Drugs & Targets

FDA issues draft guidance on genome editing safety standards

FDA issued a draft guidance for sponsors seeking approval of human gene therapy products involving genome editing technologies. When finalized, this guidance will provide recommendations for standardized methods for comprehensively assessing the safety of genome editing therapies to bring effective treatments to patients sooner.

April 17, 2026

Vol.52 No.15

Guest Editorial

FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
Draft guidance consolidates trial design updates for developers

In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies.

April 03, 2026

Vol.52 No.13

By Nicholas Richardson

Clinical Roundup

Computational biology tool automates and standardizes genome sequencing analysis, Sanford Burnham study finds

In a single experiment, scientists can decipher the entire genomes of many patient samples, animal models, or cultured cells. To fully realize the potential to study biology at this scale, researchers must be equipped to analyze the titanic troves of data generated by these new methods.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Inocras and Broad Institute researchers will release insights from TCGA cancer whole-genome analysis at AACR annual meeting

Researchers at Inocras, a bioinformatics-led precision health company, and the Broad Institute jointly announced the upcoming release of key insights from whole-genome analysis of over 8,000 public cancer whole genomes. This analysis aims to deliver one of the largest genome-wide landscapes of somatic mutations across human pan-cancers.

March 20, 2026

Vol.52 No.11

Illumina markets whole-genome sequencing solution for highly sensitive MRD research

YOU MAY BE INTERESTED IN

J. Craig Venter’s work was foundational to cancer advancement of the past 25 years

City of Hope to evaluate Quest Diagnostics’ Haystack MRD for guiding patient management in multiple cancers

FDA issues draft guidance on genome editing safety standards

FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
Draft guidance consolidates trial design updates for developers

Computational biology tool automates and standardizes genome sequencing analysis, Sanford Burnham study finds

Inocras and Broad Institute researchers will release insights from TCGA cancer whole-genome analysis at AACR annual meeting

Renew today!

Subscriber content

Never miss an issue!

Login

Illumina markets whole-genome sequencing solution for highly sensitive MRD research

YOU MAY BE INTERESTED IN

J. Craig Venter’s work was foundational to cancer advancement of the past 25 years

City of Hope to evaluate Quest Diagnostics’ Haystack MRD for guiding patient management in multiple cancers

FDA issues draft guidance on genome editing safety standards

FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters mostDraft guidance consolidates trial design updates for developers

Computational biology tool automates and standardizes genome sequencing analysis, Sanford Burnham study finds

Inocras and Broad Institute researchers will release insights from TCGA cancer whole-genome analysis at AACR annual meeting

Never miss an issue!

Login

FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
Draft guidance consolidates trial design updates for developers